Panamesine
Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ 1 and σ 2 receptors (IC 50 = 6 nM).
In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC 50 = 24 nM) and the dopamine D 2 (IC 50 = 23 nM) and D 3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development. CNS review:
Panamesine ( ; developmental code name EMD-57455) is a sigma receptor antagonist that was under development by Merck as a potential antipsychotic for the treatment of schizophrenia in the 1990s but was never marketed. It is a selective antagonist of both sigma receptor subtypes, the σ 1 and σ 2 receptors (IC 50 = 6 nM).
In addition, the major metabolite of the drug, EMD-59983, has high affinity for the sigma receptors (IC 50 = 24 nM) and the dopamine D 2 (IC 50 = 23 nM) and D 3 receptors, with potent antidopaminergic activity. Panamesine reached phase II clinical trials for schizophrenia prior to the discontinuation of its development. CNS review:
See also
List of investigational antipsychotics BMY-14802 Eliprodil Rimcazole
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371987952 under CC BY-SA 4.0; modifications have been made.